Hanno Riess - Concepedia

Author

Hanno Riess

Also Known As

Bernd D鰎ken, Bettina Schenk, H RIESS, H Riess, H. RIESS, H. Riess, HANNO RIESS, Hanno B. Riess, Hanno Riess, Heike Carnarius

520

Publications

21.3K

Citations

H-Index

152

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Humboldt-Universität zu Berlin Ludwig-Maximilians-Universität München Heidelberg University Freie Universität Berlin

About

Hanno Riess is an author at Charité - Universitätsmedizin Berlin specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	91	6.6K
2	Health Sciences	21	31	1.4K
3	Engineering	4	4	610
4	Public Health	2	2	40
5	Social Sciences	1	1	39

Hanno Riess

176

Publications

15.9K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer Helmut Oettle, Stefan Post, P. Neuhaus, JAMA	2007	2.4K
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer Helmut Oettle, P. Neuhaus, Andreas Hochhaus, JAMA	2013	1.8K
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Alok A. Khorana, Gerald A. Soff, Ajay K. Kakkar, New England Journal of Medicine	2019	683
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. A.S. Lübbe, Christian Bergemann, Hanno Riess, PubMed Magnetic FluidsPharmacotherapyAdvanced Solid TumorsClinical ExperiencesOncology	1996	653
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial Helmut Oettle, Hanno Riess, Jens Stieler, Journal of Clinical Oncology	2014	476
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. A.S. Lübbe, Christian Bergemann, W. Huhnt, PubMed Pharmaceutical ScienceEngineeringImmunologyPharmacotherapyBiomedical Engineering	1996	397
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group Uwe Pelzer, Ingo Schwaner, Jens Stieler, European Journal of Cancer OncologyPancreatic CancerGastrointestinal OncologyCancer ManagementPhase Iii-study	2011	379
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond, The Lancet Oncology Lymphoid NeoplasiaPtld-1 TrialTransplantationMedicineImmunology	2011	379
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial Marianne Sinn, Marcus Bahra, Torsten Liersch, Journal of Clinical Oncology	2017	291
Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial Uwe Pelzer, Bernhard Opitz, G. Deutschinoff, Journal of Clinical Oncology	2015	262

Page 1